

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

ACC 2011 Publication Schedule / Conference Call Details

Ladies and Gentlemen,

Findings from the Phase III MAGELLAN study of Rivaroxaban will be presented at the American College of Cardiology (ACC) Annual Scientific Session in New Orleans, USA, on April 5, 2011, 3:00 p.m. – 3:12 p.m. CEST. We cordially invite investors and analysts to participate in our conference call on this occasion.

The schedule is as follows:

Tuesday April 5, 2011	**Internet address for all information material and webcast:** www.investor.bayer.com / www.investor.bayer.de
	Press release on Rivaroxaban data presented at the ACC conference
04:00 p.m. CEST	**Investor Conference Call to discuss Rivaroxaban data presented at ACC** with Dr. Kemal Malik, Head of Global Development at Bayer Healthcare Pharmaceuticals, Dr. Frank Misselwitz, Head of Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development and Dr. Alexander Rosar, Head of Investor Relations
	Dial-in Numbers **International: +44 203 147 4695** **UK: 0203 147 4695** **US: 1 866 796 1569** **Germany: 069 710 491 413** If you are unable to participate in the conference, a recording will be available for access by touch tone telephone until April 8, 2011. A live audio broadcast (English only) will be available on the internet.
	Replay Dial-in Numbers **International: +44 121 260 4861, Passcode: 51901#** **UK: 0121 260 4861, Passcode: 51901#** **US: 646 200 5850, Passcode: 51901#** **Germany: 069 710 488 70, Passcode: 51901#**
07:00 p.m. CEST	On-demand version of the conference call webcast available on the internet.

CEST = Central European Summer Time = GMT + 2 hours

Best regards,

Bayer Investor Relations